116 related articles for article (PubMed ID: 8410117)
1. Corrected QT interval prolongation in anthracycline-treated survivors of childhood cancer.
Schwartz CL; Hobbie WL; Truesdell S; Constine LC; Clark EB
J Clin Oncol; 1993 Oct; 11(10):1906-10. PubMed ID: 8410117
[TBL] [Abstract][Full Text] [Related]
2. Is screening for abnormal ECG patterns justified in long-term follow-up of childhood cancer survivors treated with anthracyclines?
Pourier MS; Mavinkurve-Groothuis AM; Loonen J; Bökkerink JP; Roeleveld N; Beer G; Bellersen L; Kapusta L
Pediatr Blood Cancer; 2017 Mar; 64(3):. PubMed ID: 27654133
[TBL] [Abstract][Full Text] [Related]
3. Presence of prolonged dispersion of qt intervals in late survivors of childhood anthracycline therapy.
Gupta M; Thaler HT; Friedman D; Steinherz L
Pediatr Hematol Oncol; 2002 Dec; 19(8):533-42. PubMed ID: 12487828
[TBL] [Abstract][Full Text] [Related]
4. Anthracycline dose in childhood acute lymphoblastic leukemia: issues of early survival versus late cardiotoxicity.
Sorensen K; Levitt G; Bull C; Chessells J; Sullivan I
J Clin Oncol; 1997 Jan; 15(1):61-8. PubMed ID: 8996125
[TBL] [Abstract][Full Text] [Related]
5. Cardiac functions by myocardial performance index and QT dispersion in survivors of childhood lymphoblastic leukaemia.
Gulen H; Kazanci E; Mese T; Uzunkaya D; Erbay A; Tavli V; Vergin C
Minerva Pediatr; 2007 Apr; 59(2):107-13. PubMed ID: 17404560
[TBL] [Abstract][Full Text] [Related]
6. Comparison of cardiac function tests after anthracycline therapy in childhood. Implications for screening.
Jakacki RI; Larsen RL; Barber G; Heyman S; Fridman M; Silber JH
Cancer; 1993 Nov; 72(9):2739-45. PubMed ID: 8402498
[TBL] [Abstract][Full Text] [Related]
7. Prospective evaluation of early cardiac damage induced by epirubicin-containing adjuvant chemotherapy and locoregional radiotherapy in breast cancer patients.
Meinardi MT; van Veldhuisen DJ; Gietema JA; Dolsma WV; Boomsma F; van den Berg MP; Volkers C; Haaksma J; de Vries EG; Sleijfer DT; van der Graaf WT
J Clin Oncol; 2001 May; 19(10):2746-53. PubMed ID: 11352968
[TBL] [Abstract][Full Text] [Related]
8. Assessment of anthracycline-induced cardiotoxicity with electrocardiography.
Horacek JM; Jakl M; Horackova J; Pudil R; Jebavy L; Maly J
Exp Oncol; 2009 Jun; 31(2):115-7. PubMed ID: 19550402
[TBL] [Abstract][Full Text] [Related]
9. Noninvasive evaluation of late anthracycline cardiac toxicity in childhood cancer survivors.
Hudson MM; Rai SN; Nunez C; Merchant TE; Marina NM; Zalamea N; Cox C; Phipps S; Pompeu R; Rosenthal D
J Clin Oncol; 2007 Aug; 25(24):3635-43. PubMed ID: 17704413
[TBL] [Abstract][Full Text] [Related]
10. Cardiac failure and dysrhythmias 6-19 years after anthracycline therapy: a series of 15 patients.
Steinherz LJ; Steinherz PG; Tan C
Med Pediatr Oncol; 1995 Jun; 24(6):352-61. PubMed ID: 7715541
[TBL] [Abstract][Full Text] [Related]
11. Electrocardiographic changes and arrhythmias after cancer therapy in children and young adults.
Larsen RL; Jakacki RI; Vetter VL; Meadows AT; Silber JH; Barber G
Am J Cardiol; 1992 Jul; 70(1):73-7. PubMed ID: 1615874
[TBL] [Abstract][Full Text] [Related]
12. Electrophysiological effects of anthracyclines in adult survivors of pediatric malignancy.
Markman TM; Ruble K; Loeb D; Chen A; Zhang Y; Beasley GS; Thompson WR; Nazarian S
Pediatr Blood Cancer; 2017 Nov; 64(11):. PubMed ID: 28453898
[TBL] [Abstract][Full Text] [Related]
13. Exercise echocardiography in asymptomatic survivors of childhood cancer treated with anthracyclines: a prospective follow-up study.
Sieswerda E; Kremer LC; Vidmar S; De Bruin ML; Smibert E; Sjöberg G; Cheung MM; Weintraub RG
Pediatr Blood Cancer; 2010 Apr; 54(4):579-84. PubMed ID: 20014238
[TBL] [Abstract][Full Text] [Related]
14. Lack of clinically significant cardiac dysfunction during intermediate dobutamine doses in long-term childhood cancer survivors exposed to anthracyclines.
Lanzarini L; Bossi G; Laudisa ML; Klersy C; Aricò M
Am Heart J; 2000 Aug; 140(2):315-23. PubMed ID: 10925349
[TBL] [Abstract][Full Text] [Related]
15. Cardiac toxicity 4 to 20 years after completing anthracycline therapy.
Steinherz LJ; Steinherz PG; Tan CT; Heller G; Murphy ML
JAMA; 1991 Sep; 266(12):1672-7. PubMed ID: 1886191
[TBL] [Abstract][Full Text] [Related]
16. Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults.
Hequet O; Le QH; Moullet I; Pauli E; Salles G; Espinouse D; Dumontet C; Thieblemont C; Arnaud P; Antal D; Bouafia F; Coiffier B
J Clin Oncol; 2004 May; 22(10):1864-71. PubMed ID: 15143078
[TBL] [Abstract][Full Text] [Related]
17. QT dispersion and late potentials during doxorubicin therapy for non-Hodgkin's lymphoma.
Nousiainen T; Vanninen E; Rantala A; Jantunen E; Hartikainen J
J Intern Med; 1999 Apr; 245(4):359-64. PubMed ID: 10356598
[TBL] [Abstract][Full Text] [Related]
18. Diagnosis of anthracycline-induced late cardiomyopathy by exercise-spiroergometry and stress-echocardiography.
Hauser M; Gibson BS; Wilson N
Eur J Pediatr; 2001 Oct; 160(10):607-10. PubMed ID: 11686505
[TBL] [Abstract][Full Text] [Related]
19. The evaluation of left ventricular function in childhood cancer survivors by pharmacological stress echocardiography.
Elbl L; Hrstkova H; Chaloupka V; Novotny J; Michalek J
Neoplasma; 2003; 50(3):191-7. PubMed ID: 12937852
[TBL] [Abstract][Full Text] [Related]
20. Ventricular-Arterial Coupling in Breast Cancer Patients After Treatment With Anthracycline-Containing Adjuvant Chemotherapy.
Koelwyn GJ; Lewis NC; Ellard SL; Jones LW; Gelinas JC; Rolf JD; Melzer B; Thomas SM; Douglas PS; Khouri MG; Eves ND
Oncologist; 2016 Feb; 21(2):141-9. PubMed ID: 26764251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
